Efzimfotase alfa demonstrated improvements in bone health in treatment-naïve pediatric patients with hypophosphatasia achieving median difference of 1.67 vs placebo in RGI-C Score at week 25 in MULBERRY Phase III trial
World Birth Defects Day: “Behind every diagnosis is a story that deserves to be supported through strong public policies and strengthened health systems”